中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (13) :1088-1093    DOI: 10.11669/cpj.2013.13.011
��Դ����� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
�������ڶ�ͯ�ͳ�����Ѫ��ϸ����ֲԤ���������ڵ�ҩ��ѧ�о�
֣Ƽ1a,������1a,���1b*,������1a,������2,����2
1.�Ϸ�ҽ�ƴ�ѧ�Ϸ�ҽԺ,a.ҩѧ��;b.����,���� 510515;
2.�Ϸ�ҽ�ƴ�ѧ�����������ȴ�ҽѧѧԺ�����������, ���� 510515
ZHENG Ping1a, LIU Shi-ting1a, LI Chun-fu1b*, LI Li-ren1a, CHEN Ling-yun2, MA An-de2
1a.Department of Pharmacy; 1b.Department of Pediatrics,Nanfang Hospital,Southern Medical University, Guangzhou 510515, China;
2.Hygiene Detection Center,School of Public Health and Tropical Medicin,Southern Medical University, Guangzhou 510515, China

Download: PDF (1045KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �о�������ע�������ڶ�ͯ�ͳ����������Ѫ��ϸ����ֲԤ�����ߵ�ҩ��ѧ���������� ��ͯ22��,����9��,��31���������Ѫ��ϸ����ֲԤ�����߾�����ע������,����8�����к�ƶѪ������ע0.8~1 mg·kg-1, q6 h,4 d,14������ѪҺ��������ע4~5 mg·kg-1, qd,4 d,9�����˰�Ѫ��������ע0.8 mg·kg-1, q6 h,3 d,�����һ����ҩʱ,�ֱ��ڸ�ҩǰ����ע�м���ҩ��ͬʱ���ɼ�Ѫ��,��Һ��ɫ��-�������׷��ⶨѪ��������Ũ��,��DAS�������ҩ��ѧ����ģ�����,����ҩ��ѧ��������� ������ע���������������Ѫ��ϸ����ֲԤ���������ڷ��϶���ģ�͡���ͯ�ͳ�����Ҫҩ��ѧ�����ֱ�Ϊ:CL(0.4±0.2)��(0.2±0.1)L·h-1·kg-1��t1/2β(3.3±1.5)��(3.1±0.8) h��Vd(0.6±0.8)��(0.4±0.2) L·kg-1��Cav(590.4±265.3)��(572.2±214.7) μg·L-1�����˺Ͷ�ͯCL�������Բ���(P<0.05),���к�ƶѪ�����Ͷ��԰�Ѫ������t1/2β��Vd��CL��K10��K12�м���������(P<0.01)������ ������ע���������������Ѫ��ϸ����ֲԤ���������ڵ���Ҫҩ��ѧ������������,��ͯ���������,���к�ƶѪ����Vd��t1/2β��������,�б�Ҫ��չ����ҩ���⡣
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
֣Ƽa
������a
���b*
������a
������
����
�ؼ����� ������   ҩ��ѧ   ��Ѫ��ϸ����ֲ   Ԥ������   ��ͯ   ����     
Abstract�� Objective To study the pharmacokinetic profiles of intravenous busulfan in Chinese pediatric and adult patients undergoing allogeneic hematopoietic stem cell transplantation(allo-HSCT). Methods Blood samples of 22 pediatric and 9 adult patients were collected following the last dose of a 3-4 d, 12-16 doses intravenous busulfan regimen in children with thalassemia and adult leukemia patients or of a 4 d, once-daily intravenous busulfan regimen in pediatric hematologic malignancies patients. The plasma concentrations of busulfan were determined by LC/MS/MS, and the pharmacokinetic parameters of busulfan were calculated by DAS. Results The plasma concentration-time curves after the last dose intravenous busulfan in 31 patients were fitted to a two-compartment model. The main pharmacokinetic parameters in pediatric and adult patients undergoing allo-HSCT were as follow: CL(0.4±0.2) and(0.2±0.1) L·h-1·kg-1, t1/2β(3.3±1.5) and(3.1±0.8) h , Vd(0.6±0.8) and(0.4±0.2) L·kg-1, and Cav(590.4±265.3) and(572.2±214.7) μg·L-1, respectively. The CL after intravenous administration of busulfan was different between pediatric and adult patients(P<0.05). The t1/2β, Vd, CL, K10, and K12 were significantly different(P<0.01) between the pediatric patients with thalassemia and hematologic malignancies. Conclusion The inter- and intra-patient variabilities in the main pharmacokinetic parameters of intravenous busulfan in children and adults are statistically significant. The difference of pharmacokinetic parameters between children with different diseases is obvious. The t1/2β and Vd in pediatric patients with thalassemia have significant reduction. More research is warranted on intravenous busulfan pharmacokinetics in Chinese patients, and therapeutic drug monitoring and appropriate dose adjustment are recommended.
Keywords�� busulfan,   pharmacokinetics,   hematopoietic stem cell transplantation,   preparative regimen,   children,   adults     
�ո�����: 2012-07-30;
��������:

�Ϸ�ҽԺԺ������(2009C013)

ͨѶ���� ���,�� ,����ҽʦ,����,˶ʿ����ʦ �о�������Ѫ��ϸ���������Ƶ��к���Ѫ��ͯ��Ѫ���������������� Tel/Fax(020)61641921 E-mailcunfugzcn@126.com     Email: cunfugzcn@126.com
���߼��: ֣Ƽ,Ů,˶ʿ,����ҩʦ �о������ٴ�ҩѧ��ҩ������ѧ
���ñ���:   
֣Ƽa, ������a, ���b*�� .�������ڶ�ͯ�ͳ�����Ѫ��ϸ����ֲԤ���������ڵ�ҩ��ѧ�о�[J]  �й�ҩѧ��־, 2013,V48(13): 1088-1093
ZHENG Ping-a, LIU Shi-Ting-a, LI Chun-Fu-b* etc .Pharmacokinetics of Busulfan in Pediatric and Adult Patients Prior to Hematopoietic Stem Cell Transplantation[J]  Chinese Pharmaceutical Journal, 2013,V48(13): 1088-1093
��
[1] RADOMINSKA-PANDYA A,CZERNIK P J, LITTLE J M, et al.Structural and functional studies of UDP-glucuronosyltransferases.Drug Metab Rev, 1999,31(4): 817-899.
[2] MINERS J O,AND P I,MACKENZIE.Drug glucuronidation in humans.Pharmacol Ther, 1991, 51(3): 347-369.
[3] IWAI M, MARUOY, ITO M, et al.Six novel UDP-glucuronosyltransferase(UGT1A3) polymorphisms with varying activity.J Hum Genet, 2004, 49(3): 123-128.
[4] CHEN Y,CHEN S, LI X, et al.Genetic variants of human UGT1A3: Functional characterization and frequency distribution in a Chinese Han population.Drug Metab Dispos, 2006,34(9): 1462-1467.
[5] CAILLIER B,L��PINE J, TOJCIC J, et al.A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet Genomics, 2007, 17(7): 481-495.
[6] PRUEKSARITANONT T,SUBRAMANIAN R, FANG X, et al.Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization.Drug Metab Dispos, 2002,30(5): 505-512.
[7] GOOSEN T C,BAUMAN J N, DAVIS J A, et al.Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.Drug Metab Dispsos, 2007,35(8): 1315-1324.
[8] IEIRI I, NISHIMURA C, MAEDA K, et al .Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.Pharmacogenet Genomics, 2011,21(8): 495-505.
[9] EHMER U, VOGEL A, SCH��TTE J K, et al.Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.Hepatology, 2004,39(4): 970-977.
[1] ���Ӷ�,�Ƴ���,����ܿ,Ҷ����.�����򰷵���Һ��������֯�ֲ�����ҩ��ѧ[J]. �й�ҩѧ��־, 2014,49(6): 380-384
[2] �������������������*.�Ա��ҩ��ѧ��ҩЧѧӰ����о���չ[J]. �й�ҩѧ��־, 2013,23(9): 667-671
[3] �ܼ�,����,Ф��ƽ,Ԭ�ٻ�,����,����*,����*.΢͸�������о�������ɳ���ڴ����Ժ�Ѫ�е�ҩ��ѧ[J]. �й�ҩѧ��־, 2013,48(6): 466-469
[4] ��ΰ��, �Ƴɿ�, ����, ������, ������*.�ױ�����Դ���������̬ʱ��������ҩ��ѧ��Ӱ��[J]. �й�ҩѧ��־, 2013,48(4): 289-292
[5] ������, �ָ�ͨ, ����, ����, ������*.HPLC������Ѫ�������������Ũ�ȼ���ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2013,48(4): 293-296
[6] ��ʿ��, , ����Ӣ, , ������, ����Զ , ��ɺɺ, , ����*, Ԭ����*.�ʲ�����֬/���λ�Ͻ������Ʊ�������������[J]. �й�ҩѧ��־, 2013,48(4): 280-285
[7] �����٣����䣬³�������Ų��ƣ�л������������.��������������ƽ����΢����Ʊ�������ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2013,48(3): 191-194
[8] ��ΰ����㣬���࣬���������½�����³����.����ҩƷע�Ἴ��Ҫ�����Э����Զ�ͯҩ���ٴ��о���Ҫ�󼰶��ҹ���ʾ[J]. �й�ҩѧ��־, 2013,48(3): 237-240
[9] Ҷ�㷼����ӱ�ȣ�����ޱ��Ҧ���࣬��С½���α�*.����ֲ����ù����ѪҩŨ���˹�������Ԥ��ģ��[J]. �й�ҩѧ��־, 2013,48(14): 1200-1203
[10] ��ӱ��,���¢,�,����Ƽ*,������,������, ��ѧ��,֣��*.LC-MS/MS�ⶨ��������˫�ҡ�������ͪ��������ͪ���Դ�л�����Ũ��[J]. �й�ҩѧ��־, 2013,48(13): 1103-1108
[11] ��־,,����,κ���,���°�*.Һ��ɫ��-�������÷��ڷ���P-�ǵ��׽鵼����ҩ��ѧ�����е�Ӧ��[J]. �й�ҩѧ��־, 2013,48(11): 850-853
[12] ��Ԥ��,������,���ƻ�,����,������,��ϼ,�渣��*.Һ��ɫ��-�������׷��ⶨ��Ѫ���в���ɫ�ּ����л���Ũ��[J]. �й�ҩѧ��־, 2013,48(11): 904-908
[13] ������ Ҧ������ˮ���� ��Դ �� �߷��� �� *�� �ӽ���.��֥�ᵥ��TƬ�����Ʊ�����������ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2013,48(11): 976-979
[14] ������������*������������骣��������Ŵ�.�ҹ�ҩƷ˵������Ⱥ��ҩ��ѧӦ����״�о�[J]. �й�ҩѧ��־, 2013,48(11): 1036-1037
[15] ��㣬��������������������÷*.���й�ҩѧ��־����2011����й���Ʒ�Ƽ��ڿ�[J]. �й�ҩѧ��־, 2013,48(10): 813-817
Copyright 2010 by �й�ҩѧ��־